Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 8 (5) |
| Completed vs Stopped Early | 20 / 1 (3.5%) |
| Median Closed Actual Enrollment | 215 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Asan Medical Center | Seoul | 8 |
| Severance Hospital | Seoul, Seoul,50-1 Yonsei-ro/Seodaemun-gu | 6 |
| Samsung Medical Center | Seoul, Gangnam-Gu | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07449754 | Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | Phase II | RECRUITING |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Hanmi Pharmaceutical Company Limited Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.